Details of the Drug

General Information of Drug (ID: DMR3S9B)

Drug Name

Tyloxapol

Synonyms

Alevaire; Enuclene; Macrocyclon; Oxirane; Superinone; Superiuone; Tiloxapol; Tyloxapolum; Tyloxypal; Component of Alevaire; Superiuone [French]; Triton WR 1339; P-Isooctylpolyoxyethylenephenol formaldehyde polymer; Tiloxapol [INN-Spanish]; Triton A-20; Triton WR-1339; Tyloxapolum [INN-Latin]; Oxyethylated tertiary octyl-phenol-formaldehyde polymer; Triton W.R.1339; Tyloxapol [USAN:BAN:INN]; Ethylene oxide-formaldehyde-p-octylphenol copolymer; P-(1,1,3,3-Tetramethylbutyl)phenol polymer with ethylene oxide and formaldehyde; Formaldehyde, polymer with oxirane and 4-(1,1,3,3-tetra methylbutyl)phenol; Formaldehyde, polymer with oxirane and 4-(1,1,3,3-tetramethylbutyl)phenol; Phenol, 4-(1,1,3,3-tetramethylbutyl)-, polymer with formaldehyde and oxirane; Phenol, p-(1,1,3,3-tetramethylbutyl)-, polymer with ethylene oxide and formaldehyde; 4-(1,1,3,3-Tetramethylbutyl)phenol, polymer with formaldehyde & oxirane; 4-(1,1,3,3-Tetramethylbutyl)phenol, polymer with formaldehyde oxirane; 4-(1,1,3,3-tetramethylbutyl)phenol; 4-(2,4,4-trimethylpentan-2-yl)phenol

Indication

Disease Entry	ICD 11	Status	REF
Congenital alveolar dysplasia	N.A.	Approved	[1]
Cystic fibrosis	CA25	Terminated	[2]

Affected Organisms

Humans and other mammals

ATC Code

R05CA01: Tyloxapol

R05CA: Expectorants

R05C: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS

R05: COUGH AND COLD PREPARATIONS

R: RESPIRATORY SYSTEM

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski):
0

Molecular Weight

280.4

Logarithm of the Partition Coefficient

Not Available

Rotatable Bond Count

Hydrogen Bond Donor Count

Hydrogen Bond Acceptor Count

Chemical Identifiers

Formula: C17H28O3
IUPAC Name: formaldehyde;oxirane;4-(2,4,4-trimethylpentan-2-yl)phenol
Canonical SMILES: CC(C)(C)CC(C)(C)C1=CC=C(C=C1)O.C=O.C1CO1
InChI: InChI=1S/C14H22O.C2H4O.CH2O/c1-13(2,3)10-14(4,5)11-6-8-12(15)9-7-11;1-2-3-1;1-2/h6-9,15H,10H2,1-5H3;1-2H2;1H2
InChIKey: MDYZKJNTKZIUSK-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 71388
ChEBI ID: CHEMBL141517
CAS Number: 25301-02-4
UNII: Y27PUL9H56
DrugBank ID: DB06439
TTD ID: D00ARN

Drug Pharmacogenomic Perturbation (DPP)^NEW

Click to Jump to the Detailed DPP Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nuclear factor NF-kappa-B (NFKB)	TTSXVID	NFKB1_HUMAN ; NFKB2_HUMAN ; TF65_HUMAN ; RELB_HUMAN ; REL_HUMAN	Inhibitor	[3]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Tyloxapol FDA Label
2	Tyloxapol inhibits NF-kappa B and cytokine release, scavenges HOCI, and reduces viscosity of cystic fibrosis sputum. American Journal of Respiratory and Critical Care Medicine. 10/1996; 154(3 Pt 1):783-8.
3	Study of influence of additives of tyloxapol on the chromatographic characteristics of the model compounds: the comparative characterization of micellar mobile phases of tyloxapol and Triton X-100. Biomed Chromatogr. 2009 Jul;23(7):700-6.